Shield-and-Amplify Nanoparticle Vaccines Retune Immunodominance for Broad Protection against SARS-CoV-2
Abstract Antigenic variation severely constrains the durability and breadth of vaccine-induced protection against rapidly evolving viruses. Although conserved epitopes can support cross-variant immunity, antibody responses to viral glycoproteins are often biased toward exposed, mutable immunodominant epitopes, leaving conserved protective sites subdominant. We previously identified a cryptic, conserved class 5 epitope (the 6D6/7D6 epitope) on the SARS-CoV-2 receptor-binding domain (RBD) capable of eliciting broad cross-neutralization. Here, we present a modular “shield-and-amplify” nanoparticle vaccination strategy to redirect immunodominance toward this subdominant epitope. We engineered site-specific N-linked glycans─alongside the native N343 glycan to mask variable immunodominant regions while preserving accessibility to the class 5 epitope. The resulting glycan-masked RBD antigen (RGM) was displayed on p239 nanoparticles via nanobody-mediated assembly, yielding multivalent RGM@p239 immunogens. Antigenic profiling revealed that glycan shielding preserved recognition by 6D6 and 7D6 antibodies while reducing binding of representative class 1–4 antibodies by at least 80%. In immunized animals, RGM@p239 enriched 7D6-competitive serum antibodies blocking approximately 70–80% of serum binding to RGM and broadened cross-variant neutralization against 8 representative variant strains, including detectable activity against Omicron lineages. Furthermore, RGM@p239 reduced disease severity after Omicron EG.1 challenge in a hamster model. These results support a model in which glycan shielding and nanoparticle multivalency act as complementary immune-focusing modules: shielding attenuates competing responses, while multivalency amplifies responses to conserved subdominant epitopes. This study establishes a nanovaccine design strategy to address antigenic variation by focusing immunity on conserved viral vulnerabilities.
Authors
- 张玉云
- Hai Yu (ORCID: https://orcid.org/0000-0002-4378-0532)
- Ting Wu (ORCID: https://orcid.org/0009-0002-4931-2251)
- Wenhui Xue
- 刘宏景
- Lunzhi Yuan (ORCID: https://orcid.org/0000-0001-7480-0287)
- Ningshao Xia (ORCID: https://orcid.org/0000-0003-0179-5266)
- Miaolin Lan
- Zihao Chen (ORCID: https://orcid.org/0000-0002-8221-0751)
- Ming Zhou (ORCID: https://orcid.org/0000-0002-2926-3133)
- Shaowei Li (ORCID: https://orcid.org/0000-0002-3374-1038)
- Yarong Zeng
- Lingyan Cui
- Jinjin Li
- Hai Li
- Ying Gu
- Longmei Zhang
- Sibo Zhang
- Yali Zhang
- Lin Chen
- Jian Ma
- Hong Wang
- Kun Wu
- Tingting Li
- Jin Xiao
Institutions
- Xiamen University (CN)
Publication Details
- Journal
- ACS Nano
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1021/acsnano.6c13208
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Fujian Province
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities